The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | The current state of cardiac transplantation for AL and ATTR amyloidosis
Ronald Witteles, MD, Stanford University, Stanford, CA, provides insight into the landscape of cardiac transplantation for light chain (AL) and transthyretin (ATTR) amyloidosis. Historically, outcomes of heart transplantation were very poor in these patient populations; however, significant progress has been made over the past decades. In patients with AL amyloidosis, extensive screening for significant extra-cardiac involvement is necessary, and clinicians must ensure good light chain control post-transplant is possible. In patients with ATTR amyloidosis with variant disease and younger patients with wild-type disease, transplantation should be considered if heart failure is severe, and Dr Witteles highlights that the outcomes of transplantation in this population are excellent. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Pfizer, Alnylam, BridgeBio, Novo Nordisk, Astra Zeneca, Janssen, Alexion
